| 摘要 |
Carbohydrate-based products (CBP), methods for synthesis of CBP and use of CBP are claimed. Also claimed is the treatment of a patient in connection with and after xenotransplantation of a non-transgenic or a transgenic organ, via injection with one or more of alpha 1-3-bound galactopyranosyl-galactopyranose (Gal alpha 1-3Gal) or its alpha - or beta -glycoside, Gal alpha 1-3Gal beta 1-4GlcNAc, other trisaccharide, Gal alpha 1-3Gal beta 1-4GlcNAc beta 1-3Gal or higher oligosaccharide containing Gal alpha 1-3Gal, modified alpha 1-3-bound galactopyranosyl-galactopyranose, modified trisaccharide of the type Gal alpha 1-3Gal beta 1-4GlcNAc, other modified trisaccharide, modified tetrasaccharide of the type Gal alpha 1-3Gal beta 1-4GlcNAc beta 1-3Gal or higher oligosaccharide, modified beta glycoside or a product which is di, tri, oligo or multifunctional concerning one or more of the above. - Treatment is by passage of plasma through material containing the material mentioned above. The treatment includes the use of PEG-modified alpha-galactosidase. |
